Top

Strahlentherapie und Onkologie

Published in:

01-03-2014 | Original article

Interstitial brachytherapy for eyelid carcinoma

Outcome analysis in 60 patients

Authors: M. Krengli, MD, L. Masini, A.M. Comoli, E. Negri, L. Deantonio, A. Filomeno, G. Gambaro

Published in: Strahlentherapie und Onkologie | Issue 3/2014

Abstract

Background

Eyelid cancer is a therapeutic challenge due to the cosmetic and functional implications of this anatomical region and the objectives of therapy are tumor control, functional and cosmetic outcome.

Aim

The present study was performed to analyze local control, toxicity, functional and cosmetic results in patients with eyelid carcinoma treated by interstitial brachytherapy.

Material and methods

In this study 60 patients with eyelid carcinoma were treated by interstitial brachytherapy using iridium (¹⁹²Ir) wires with a linear activity of 1.2–1.7 mCi/cm. The prescription dose was 51–70 Gy (mean 65 Gy, median 66 Gy).

Results

Of the 60 patients 51 (85.0 %) had received no prior treatment, 4 (6.7 %) had received previous surgery with positive or close margins and 5 (8.3 %) had suffered local recurrence after surgery. Of the tumors 52 (86.7 %) were basal cell carcinoma, 7 (11.7 %) squamous cell carcinoma and 1 (1.7 %) Merkel cell carcinoma. Clinical stage of the 51 previously untreated tumors was 38 T1N0, 12 T2N0 and 1 T3N0. Mean follow–up was 92 months (range 6–253 months). Local control was maintained in 96.7 % of patients. Late effects higher than grade 2 were observed in 3.0 % of cases. Functional and cosmetic outcomes were optimal in 68.4 % of patients.

Conclusion

Interstitial brachytherapy for carcinoma of the eyelid can achieve local control, cosmetic and functional results comparable to those of surgery.

Anonymous (2009) Cancer therapy evaluation program. Common terminology criteria for adverse events, version 4.0. DCTD, NCI, DHHS

Avril MF, Auperin A, Margulis A et al (1997) Basal cell carcinoma at the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer 76:100–106PubMedCentralPubMedCrossRef

Azad S, Choudhary V (2011) Treatment results of high dose rate interstitial brachytherapy in carcinoma of eye lid. J Cancer Res Ther 7:157–161PubMedCrossRef

Brualla L, Sempau J, Zaragoza FJ et al (2013) Accurate estimation dose distributions inside an eye irradiated with 106Ru plaques. Strahlenther Onkol 189:68–73PubMedCrossRef

Conill C, Sanchez-Reyes A, Molla M, Vitalta A (2004) Brachytherapy with ¹⁹²Ir as treatment of carcinoma of the tarsal structure of the eyelid. Int J Radiat Oncol Biol Phys 59:1326–1329PubMedCrossRef

Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341–1346PubMedCrossRef

Daly NJ, De Lafontan B, Combes PF (1984) Results of the treatment of 165 lid carcinomas by iridium wire implant. Int J Radiat Oncol Biol Phys 10:455–459PubMedCrossRef

Donaldson MJ, Sullivan TJ, Whitehead KJ, Williamson RM (2002) Squamous cell carcinoma of the eyelids. Br J Ophthalmol 86:1161–1165PubMedCentralPubMedCrossRef

Edge SB, Byrd DR, Compton CC et al (2010) American Joint Commission on Cancer. AJCC cancer staging manual. 7th edn. Springer, Berlin Heidelberg New York Tokio

10.

Hata M, Koike I, Maegawa J et al (2012) Radiation therapy for primary carcinoma of the eyelid: tumor control and visual function. Strahlenther Onkol 188:1102–1107PubMedCrossRef

11.

Malhotra R, Huilgol SC, Huynh NT, Selva D (2004) The Australian Mohs database: periocular squamous cell carcinoma. Ophthalmology 111:617–623PubMedCrossRef

12.

Malhotra R, Huilgol SC, Huynh NT, Selva D (2004) The Australian Mohs database: periocular basal cell carcinoma outcome at 5-year follow-up. Ophthalmology 111:631–636PubMedCrossRef

13.

Martinez-Monge R, Gomez-Iturriaga A (2007) High-dose-rate brachytherapy in lower eyelid cancer. Brachytherapy 6:227–229PubMedCrossRef

14.

Murchison AP, Walrath JD, Washington CV (2011) Non-surgical treatments of primary, non-melanoma eyelid malignancies: a review. Clin Experiment Ophthalmol 39:65–83PubMed

15.

Petsuksiri J, Frank SJ, Garden AS et al (2008) Outcomes after radiotherapy for squamous cell carcinoma of the eyelid. Cancer 112:111–118PubMedCrossRef

16.

Rio E, Bardet E, Ferron C et al (2005) Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases. Int J Radiat Oncol Biol Phys 63:753–757PubMedCrossRef

17.

Schlienger P, Brunin F, Desjardins L et al (1996) External radiotherapy for carcinoma of the eyelid: report of 850 cases treated. Int J Radiat Oncol Biol Phys 34:277–287PubMedCrossRef

18.

Stannard C, Maree G, Munro R et al (2011) Iodine-125 orbital brachytherapy with a prosthetic implant in situ. Strahlenther Onkol 187:322–327PubMedCrossRef

19.

Swanson E, Amdur RJ, Mendenhall WM et al (2009) Radiotherapy for basal cell carcinoma of the medial canthus region. Laryngoscope 119:2366–2368PubMedCrossRef

20.

Willich N (2012) Technical and methodical developments of radiation oncology from a physician’s point of view. Strahlenther Onkol 188:253–262PubMedCrossRef

Title: Interstitial brachytherapy for eyelid carcinoma
Outcome analysis in 60 patients
Authors: M. Krengli, MD
L. Masini
A.M. Comoli
E. Negri
L. Deantonio
A. Filomeno
G. Gambaro
Publication date: 01-03-2014
Publisher: Springer-Verlag
Published in: Strahlentherapie und Onkologie / Issue 3/2014
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0495-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Interstitial brachytherapy for eyelid carcinoma

Outcome analysis in 60 patients

Abstract

Background

Aim

Material and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aim

Material and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2014

Erratum to: Androgen receptor expression

The Erlangen Dose Optimization trial for low-dose radiotherapy of benign painful elbow syndrome

Time evaluation of image-guided radiotherapy in patients with spinal bone metastases

Neoadjuvante Kurzzeitbestrahlung mit anschließender Chemotherapie oder simultane Radiochemotherapie bei lokal nicht sicher kurativ resektablen Rektumkarzinomen

Erratum to: Fibroblast growth factor 2 is of prognostic value for patients with locally advanced squamous cell carcinoma of the head and neck

Gemcitabin- oder Capecitabin-basierte Radiochemotherapie beim lokal fortgeschrittenen Pankreaskarzinom (SCALOP)